Connect with us

Business

Yen Sell-off Breaks; Still Susceptible to Lessening Bets

Published

on

Over the previous 2 sessions, the American dollar has increased in excess of two-percent against the Japanese Yen, which is its largest 2-day recovery ever since 2011 October, immediately after Yoshihiko Noda, the Prime Minister of Japan, headed for a sudden voting during the coming month i.e. on 16th December 2012. The parliament’s lower house was completely dispersed recently on November 16th 2012.

The prominent leader of the major opponent Liberal Democratic Political Party, Shinzo Abe, who is more likely to be the next leader of Japan, invited for the Central Bank of the nation on Thursday (November 15th 2012) in order to approve interest rates of 0 or lower to encourage lending. The dollar was precisely plane as opposed to the Yen at around 81.18-yen, with sellers alluding to a huge options blockade at 81.50-yen, and nation’s stop-loss demands positioned well above that point.

It attained a six and half month high of around 81.46-yen on November 15th on the well-known EBS trading platform, and many market analysts informed that it could increase in the direction of 82-yen if the BOJ (Bank of Japan), which is holding a policy conference during the coming week, suggested that it could improve further. Some of the leading market experts told that while the American dollar carry on to grind upper, further quick and spiky increases were less possible during the near period.

A senior economist functioning at the famous Mizuho Corporate Bank, Colin Asher said that they have actually had a somewhat considerable shift in the past couple of days; hence they’ve possibly witnessed a mass of the initial shifts. It has been said that some shareholders with relatively short-range prospects are more likely to obtain profits following such great shifts, and most of the shareholders with long-term prospects will be quite satisfied to be situated in their present locations on the outlook that the improvement will carry on.

Some market strategists told that the present weakness of the Japanese Yen may not continue if the Bank of Japan dissatisfies during the coming week by not setting the ground for additional lessening. The yen, which is normally observed as a secured haven at times of economic ambiguity, could increase further if concerns regarding the United States fiscal cliff rise, and worries about the European region debt crisis intensify.

An international FX strategist working at the popular Credit Suisse located in Zurich, Marcus Hettinger recently told that the fundamental propeller is still the rate of interest discrepancy between the yen and dollar, which is extremely thin, and they need to anticipate what occurs after the upcoming elections.

Business

Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)

Published

on

By

Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading

Biotech

Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)

Published

on

Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading

Biotech

Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)

Published

on

Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading
Advertisement

Trending